Loading...

Oncternal Therapeutics, Inc.

ONCT•NASDAQ
Healthcare
Biotechnology
$0.53
$-0.17(-24.12%)

Oncternal Therapeutics, Inc. (ONCT) Stock Overview

Explore Oncternal Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.8/100

Key Financials

Market Cap1.6M
P/E Ratio-0.05
EPS (TTM)$-11.69
ROE-1.78%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.40

ONCT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Oncternal Therapeutics, Inc. (ONCT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.40.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.05 and a market capitalization of 1.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ONCTStats details for ONCT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$28.00
Average$28.00
High$28.00

Company Profile

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

CEO

James B. Breitmeyer

Employees

27

Headquarters

12230 El Camino Real, San Diego, CA

Founded

2004

Frequently Asked Questions

;